Suppr超能文献

类风湿关节炎的多病共患负担:一项基于人群的队列研究。

Multimorbidity Burden in Rheumatoid Arthritis: A Population-based Cohort Study.

机构信息

T.M. Gunderson, MS, Department of Health Sciences Research, Mayo Clinic, Rochester.

E. Myasoedova, MD, PhD, C.S. Crowson, PhD, Department of Health Sciences Research, and Division of Rheumatology, Department of Internal Medicine, Mayo Clinic, Rochester.

出版信息

J Rheumatol. 2021 Nov;48(11):1648-1654. doi: 10.3899/jrheum.200971. Epub 2021 Feb 15.

Abstract

OBJECTIVE

To estimate the prevalence and incidence of multimorbidity (MM) in a population-based cohort of patients with rheumatoid arthritis (RA) compared to subjects without RA.

METHODS

Between 1999-2013, residents of Olmsted County, Minnesota with incident RA who met the 1987 American College of Rheumatology criteria were compared to age- and sex-matched non-RA subjects from the same population. Twenty-five chronic comorbidities from a combination of the Charlson, Elixhauser, and Rheumatic Disease Comorbidity Indices were included, excluding rheumatic comorbidities. The Aalen-Johansen method was used to estimate the cumulative incidence of MM (MM2+; ≥ 2 chronic comorbidities) or substantial MM (MM5+; ≥ 5), adjusting for the competing risk of death.

RESULTS

The study included 597 patients with RA and 594 non-RA subjects (70% female, 90% White, mean age 55.5 yrs). At incidence/index date, the prevalence of MM2+ was higher in RA than non-RA subjects (38% RA vs 32% non-RA, = 0.02), whereas prevalence of MM5+ was similar (5% RA vs. 4% non-RA, = 0.68). During follow-up (median 11.6 yrs RA, 11.3 yrs non-RA), more patients with RA developed MM2+ (214 RA vs 188 non-RA; adjusted HR 1.39, 95% CI 1.14-1.69). By 10 years after RA incidence/index, the cumulative incidence of MM2+ was 56.5% among the patients with RA (95% CI 56.5-62.3%) compared with 47.9% among the non-RA (95% CI 42.8-53.7%). Patients with RA showed no evidence of increase in incidence of MM5+ (adjusted HR 1.17, 95% CI 0.93-1.47).

CONCLUSION

Patients with RA have both a higher prevalence of MM at the time of RA incidence as well as increased incidence thereafter.

摘要

目的

在类风湿关节炎(RA)患者的基于人群队列中,与无 RA 的患者相比,估计多种合并症(MM)的患病率和发病率。

方法

1999-2013 年,在明尼苏达州奥姆斯特德县发现的符合 1987 年美国风湿病学会标准的 RA 患者与同一人群中年龄和性别匹配的非 RA 患者进行了比较。纳入了 Charlson、Elixhauser 和风湿性疾病合并症指数的组合中的 25 种慢性合并症,不包括风湿性合并症。使用 Aalen-Johansen 方法估计 MM(MM2+;≥2 种慢性合并症)或大量 MM(MM5+;≥5 种)的累积发病率,调整死亡的竞争风险。

结果

研究纳入了 597 例 RA 患者和 594 例非 RA 患者(70%为女性,90%为白人,平均年龄为 55.5 岁)。在发病/指数日期,RA 患者的 MM2+患病率高于非 RA 患者(38%RA 比 32%非 RA, = 0.02),而 MM5+的患病率相似(5%RA 比 4%非 RA, = 0.68)。在随访期间(RA 中位数为 11.6 年,非 RA 中位数为 11.3 年),更多的 RA 患者发生了 MM2+(214 例 RA 比 188 例非 RA;调整后的 HR 为 1.39,95%CI 为 1.14-1.69)。在 RA 发病/指数后 10 年,RA 患者的 MM2+累积发病率为 56.5%(95%CI 为 56.5-62.3%),而非 RA 患者为 47.9%(95%CI 为 42.8-53.7%)。RA 患者的 MM5+发病率无增加迹象(调整后的 HR 为 1.17,95%CI 为 0.93-1.47)。

结论

RA 患者在发病时既有更高的 MM 患病率,发病后又有更高的发病率。

相似文献

7
Comorbidity in arthritis.关节炎中的合并症
J Rheumatol. 1999 Nov;26(11):2475-9.

引用本文的文献

3
From Multimorbidity to Network Medicine in Patients with Rheumatic Diseases.从风湿性疾病患者的多重疾病到网络医学
Rheumatol Ther. 2025 Feb;12(1):1-24. doi: 10.1007/s40744-024-00724-8. Epub 2024 Nov 27.
4
JAK inhibitors: an evidence-based choice of the most appropriate molecule.JAK抑制剂:基于证据的最合适分子的选择。
Front Pharmacol. 2024 Oct 29;15:1494901. doi: 10.3389/fphar.2024.1494901. eCollection 2024.
5
Understanding the multiple dimensions of ageing: 5Ms for the rheumatologist.理解衰老的多维度:风湿病学家的 5M。
Lancet Rheumatol. 2024 Dec;6(12):e892-e902. doi: 10.1016/S2665-9913(24)00230-3. Epub 2024 Nov 11.

本文引用的文献

7
Tools for the Assessment of Comorbidity Burden in Rheumatoid Arthritis.类风湿关节炎合并症负担评估工具
Front Med (Lausanne). 2018 Feb 16;5:39. doi: 10.3389/fmed.2018.00039. eCollection 2018.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验